Observational Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Oct 21, 2022; 28(39): 5764-5783
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5764
Table 2 Characteristics of classified enrolled population according to Child-Pugh in the metabolic profiling study
Clinical parameters
PBC-A (n = 26)
PBC-B (n = 19)
PBC-C (n = 9)
AIH-A (n = 17)
AIH-B (n = 9)
Age (mean, range) (yr), n54 (38, 68)57.11 (40, 73)59.33 (51, 67)52.35 (17, 75)59.11 (36, 73)
Sex (Male/Female), n6/203/160/92/151/8
AST (U/L) median, range62.77 (20, 210)182.62 (14, 1300)113.27 (35, 235)122.28 (23, 961)256.78 (64, 472)
ALT (U/L) median, range74.18 (15, 293)130.32 (12, 734)84.51 (17, 236)100.54 (10, 780)253.11 (103, 598)
ALP (U/L) median, range276.41 (75, 53)352.73 (79, 913)211.43 (55, 483)230.33 (57, 795)258.78 (46, 738)
γ-GT (U/L) median, range380.18 (40, 631)281.77 (40, 744)103.49 (32, 235)166.46 (26, 654)393.89 (73, 957)
TBA (μmol/L) median, range31.04 (2.9, 09.3)75.16 (2.7, 295.7)127.37 (23.4, 267.5)116.46 (1, 1335)144.29 (15, 379)
TBiL (μmol/L) median, range19.7 (5.6, 48.8)81.0 (11.3, 306.5)181.62 (17.7, 825.8)48.33 (6.5, 229.5)166.23 (50.0, 543.9)
DBIL (μmol/L) median, range9.18 (2.4, 32.0)48.3 (4.1, 207.9)99.71 (6.6, 407.4)27.40 (2.1, 139.3)101.24 (30.6, 300.8)
Liver cirrhosis (%)0.38 (10/26)0.84 (16/19)1 (9/9)0.47 (8/17)0.33 (3/9)
Liver biopsy (%)0.35 (9/26)0.05 (1/19)0 (0/9)0.64 (11/17)0.33 (3/9)
Positive of AMA (%)80 (21/26)80 (15/19)89 (8/9)0 (0/17)0 (0/9)
Positive of ANA (%)73 (19/26)52 (10/19)44 (4/9)100 (17/17)100 (9/9)
PBC: Primary biliary cirrhosis; AIH: Autoimmune hepatitis; AST: Aspartatetransaminase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; γ-GT: γ-glutamyl transpeptidase; TBiL: Totalbilirubin; DBiL: Direct bilirubin; TBA: Total bile acid; AMA: Anti-mitochondrial antibody; ANA: Anti-nuclear antibody. All data are presented as median and range. Statistically significant differences between controls and patients were determined by the rank sums Mann-Whitney.